a month ago
IDYA
AnalystsYigal NochomovitzYigal Nochomovitz's Stock Forecasts
AnalystsYigal Nochomovitz
Sectors:
Analyst Ranking
Top 8%
#335 out of 4565 analysts
Average Return
+9.11%
Win Rate
41%75 out of 182
Risk vs Reward
Poor
Good
Yigal Nochomovitz's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Applied Therapeutics IncAPLT | +640.00% | $0.80 | $5.92 | 2023-04-05 - 2024-04-04 | Strong Buy |
Harpoon Therapeutics IncHARP | +381.72% | $4.76 | $22.93 | 2023-09-18 - 2024-02-26 | Strong Buy |
Reata Pharmaceuticals IncRETA | +334.02% | $38.27 | $166.10 | 2022-11-09 - 2023-08-01 | Strong Buy |
Harpoon Therapeutics IncHARP | +327.80% | $5.36 | $22.93 | 2023-10-24 - 2024-02-26 | Strong Buy |
Arvinas IncARVN | +234.49% | $14.76 | $49.37 | 2023-10-24 - 2024-02-14 | Strong Buy |
Yigal Nochomovitz Analyst Color
Get additional color on Yigal Nochomovitz's coverage of popular stocks
2 months ago
MGNX
2 months ago
KRYS
2 months ago
APLT
3 months ago
ARCT
4 months ago
ARDX
4 months ago
MGNX
10 months ago
BMEA
a year ago
RARE
a year ago
LXRX
a year ago
APLS
a year ago
MRUS
Yigal Nochomovitz's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Crispr Therapeutics AgCRSP | 16 | Strong Buy | $89.00 | +65.64% | Maintains | 8 days ago |
Proqr Therapeutics NvPRQR | 3 | Hold | $2.00 | +2.04% | Maintains | 8 days ago |
Lenz Therapeutics IncLENZ | 1 | Strong Buy | $34.00 | +120.06% | Initiates Coverage On | 16 days ago |
Ideaya Biosciences IncIDYA | 2 | Strong Buy | $60.00 | +55.36% | Maintains | a month ago |
Macrogenics IncMGNX | 9 | Strong Buy | $25.00 | +73.97% | Maintains | 2 months ago |
Rigel Pharmaceuticals IncRIGL | 4 | Strong Buy | $4.00 | +263.64% | Maintains | 2 months ago |
Zai Lab LtdZLAB | 7 | Strong Buy | $66.00 | +319.31% | Maintains | 2 months ago |
Krystal Biotech IncKRYS | 1 | Strong Buy | $195.00 | +25.26% | Maintains | 2 months ago |
Harpoon Therapeutics IncHARP | 9 | Hold | $23.00 | -0.04% | Downgrades | 2 months ago |
Arrivent Biopharma IncAVBP | 1 | Strong Buy | $30.00 | +93.05% | Initiates Coverage On | 2 months ago |
Applied Therapeutics IncAPLT | 4 | Strong Buy | $7.00 | +65.48% | Maintains | 2 months ago |
Arvinas IncARVN | 7 | Hold | $55.00 | +74.05% | Downgrades | 2 months ago |
Arcturus Therapeutics Holdings IncARCT | 5 | Strong Buy | $48.00 | +83.42% | Maintains | 3 months ago |
Olema Pharmaceuticals IncOLMA | 1 | Strong Buy | $20.00 | +103.46% | Initiates Coverage On | 3 months ago |
Ardelyx IncARDX | 6 | Strong Buy | $14.00 | +121.87% | Maintains | 4 months ago |
Mirati Therapeutics IncMRTX | 11 | Hold | $59.00 | +0.51% | Downgrades | 4 months ago |
Apellis Pharmaceuticals IncAPLS | 10 | Strong Buy | $67.00 | +39.79% | Maintains | 4 months ago |
Biomea Fusion IncBMEA | 6 | Strong Buy | $90.00 | +759.60% | Reiterates | 5 months ago |
Beigene LtdBGNE | 3 | Strong Buy | $285.00 | +91.84% | Maintains | 6 months ago |
Aldeyra Therapeutics IncALDX | 8 | Strong Buy | $8.00 | +103.05% | Maintains | 6 months ago |
Rain Oncology IncRAIN | 4 | Hold | $1.00 | -17.36% | Maintains | 7 months ago |
Eiger Biopharmaceuticals IncEIGRQ | 3 | Strong Buy | $90.00 | +5,117.39% | Maintains | 8 months ago |
Gracell Biotechnologies IncGRCL | 2 | Strong Buy | $11.00 | +7.32% | Maintains | 8 months ago |
Galera Therapeutics IncGRTX | 2 | Hold | $0.25 | +20.77% | Maintains | 8 months ago |
Arcus Biosciences IncRCUS | 5 | Strong Buy | $44.00 | +198.71% | Maintains | 8 months ago |
Atara Biotherapeutics IncATRA | 7 | Strong Sell | $1.40 | +100.00% | Maintains | 8 months ago |
Merus NvMRUS | 12 | Strong Buy | $46.00 | +2.38% | Maintains | 9 months ago |
Reata Pharmaceuticals IncRETA | 8 | Hold | $172.50 | +0.08% | Downgrades | 9 months ago |
Syndax Pharmaceuticals IncSNDX | 4 | Strong Buy | $35.00 | +70.15% | Maintains | 9 months ago |
Ultragenyx Pharmaceutical IncRARE | 10 | Strong Buy | $133.00 | +203.31% | Maintains | a year ago |
Lexicon Pharmaceuticals IncLXRX | 5 | Strong Buy | $8.00 | +419.48% | Maintains | a year ago |
Unity Biotechnology IncUBX | 6 | Strong Buy | $6.00 | +305.41% | Maintains | a year ago |
Zymeworks IncZYME | 9 | Strong Buy | $18.00 | +121.95% | Maintains | a year ago |
Oric Pharmaceuticals IncORIC | 4 | Strong Buy | $8.00 | N/A | Maintains | a year ago |
Cellectis SaCLLS | 2 | Strong Buy | $16.00 | N/A | Maintains | a year ago |
Fate Therapeutics IncFATE | 3 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Calliditas Therapeutics AbCALT | 1 | Strong Buy | $79.00 | N/A | Maintains | a year ago |
Prokidney CorpPROK | 1 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 2 years ago |
Opthea LtdOPT | 2 | Strong Buy | $44.00 | N/A | Maintains | 2 years ago |
Innate Pharma SaIPHA | 1 | Strong Buy | $12.00 | N/A | Maintains | 2 years ago |
Ovid Therapeutics IncOVID | 4 | Hold | $2.50 | N/A | Maintains | 2 years ago |
Caribou Biosciences IncCRBU | 4 | Strong Buy | $38.00 | N/A | Maintains | 2 years ago |
Aerie Pharmaceuticals IncAERI | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Shattuck Labs IncSTTK | 1 | Strong Buy | $13.00 | N/A | Initiates Coverage On | 2 years ago |
Dicerna Pharmaceuticals IncDRNA | 2 | Hold | $32.00 | N/A | Downgrades | 3 years ago |
Acceleron Pharma IncXLRN | 1 | Strong Buy | $171.00 | N/A | Maintains | 3 years ago |
Puma Biotechnology IncPBYI | 5 | Strong Buy | $70.00 | N/A | Maintains | 5 years ago |
Loxo Oncology IncLOXO | 6 | Strong Buy | $213.00 | N/A | Maintains | 5 years ago |
Keryx Biopharmaceuticals IncKERX | 2 | Hold | $4.00 | N/A | Maintains | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.